Kinfo
Arcus Biosciences, Inc. logo

Arcus Biosciences, Inc.

RCUSNYSEHealthcare·US · USD
$17.34
-0.44 (-2.45%)
Prices as of November 13, 2026 · live

Price

Key statistics

Valuation
Market cap2.56B USD
Enterprise value2.32B USD
Trailing P/E-5.40
Forward P/E-6.08
PEG ratio0.00
Price / sales27.07
Price / book6.70
Profitability
Gross margin0.00%
Operating margin-475.00%
Profit margin0.00%
Return on assets-33.13%
Return on equity-114.11%
Income (TTM)
Revenue100.00M USD
Gross profit-373.00M USD
EBITDA-465.00M USD
Net income-453.00M USD
Diluted EPS-$3.64
Rev. growth (YoY)-65.40%
Balance sheet
Total cash630.00M USD
Total debt241.00M USD
Debt / equity67.32
Current ratio3.34
Book value / share$2.81
Cash flow (TTM)
Operating cash flow-465.00M USD
Levered free cash flow-274.75M USD
Shares & price
Shares outstanding127.00M
Float107.18M
Held by institutions66.75%
Beta1.09
50-day MA$23.33
200-day MA$24.53
52-week high$31.74
52-week low$17.43
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-11-04-0.89-1.00−12.36%2026-07-233.323.52+6.02%2026-05-202.913.09+6.19%
About Arcus Biosciences, Inc.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies and combination medicines. The company is building a portfolio of differentiated small molecules and antibodies designed to target key biological pathways involved in tumor growth and immune response. Its current work centers on oncology programs across several solid tumor areas, including lung, gastrointestinal, kidney, and pancreatic cancers. Arcus Biosciences also develops therapies intended to improve how cancer treatments are combined and used in clinical practice, with an emphasis on novel mechanisms such as immuno-oncology and targeted oncology. Headquartered in Hayward, California, Arcus Biosciences operates as a research-driven company working with collaborators to advance investigational medicines through clinical development and toward potential commercialization.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Terry J. Rosen Ph.D.
Employees
601
Headquarters
Hayward, CA, United States

Frequently asked questions about Arcus Biosciences, Inc.